CSL Behring agreed to acquire Calimmune for $91M upfront plus up to $325M in performance-based milestones over ~8+ years (~$416M total). The deal added the preclinical CAL-H stem cell gene therapy for sickle cell disease/beta-thalassemia plus Calimmune's Select+ enrichment and Cytegrity manufacturing platform technologies. CSL later refocused away from lentiviral gene therapy.